Albertsons Companies, Inc. (ACI) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session reveal strong growth in pharmacy and digital sales, optimistic guidance, and effective cost savings initiatives. Despite concerns about inflation and promotional environment, the company's strategic investments in technology and customer engagement are promising. Share repurchase plans and improved EPS guidance also contribute positively. Overall, these factors suggest a positive stock price movement over the next two weeks.
Key Financial Performance
Identical Sales 2.4% increase year-over-year. This growth was achieved despite a 10 to 20 basis point headwind from the government shutdown and delayed SNAP funding. The increase reflects targeted price investments and resilience in the business model.
Digital Sales 21% increase year-over-year. This growth is attributed to the scalability and customer proximity of the store-based fulfillment model, as well as the adoption of new digital features like AI shopping assistants.
Adjusted EBITDA $1.039 billion, reflecting disciplined execution and purposeful investments in technology and customer value propositions.
Pharmacy and Health Sales 18% increase year-over-year. Growth was driven by strong execution in immunization offerings, GLP-1 therapies, and core prescriptions.
Gross Margin 27.4%, a decline of 55 basis points year-over-year, excluding fuel and LIFO. The decline reflects the mix shift impact of digital and pharmacy sales and targeted price investments, partially offset by productivity benefits.
Selling and Administrative Expense Rate 24.9%, down 33 basis points year-over-year, excluding fuel. This improvement reflects disciplined cost management and productivity initiatives.
Loyalty Membership 49.8 million members, a 12% increase year-over-year. Growth was driven by program enhancements and simplification, leading to deeper engagement and higher spending by members.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI-powered shopping assistant: Introduced to redefine shopping experience with natural language interaction, personalized recommendations, and smarter basket building.
Ask AI search capability: Delivered a 10% increase in basket size for users, indicating potential revenue growth.
Autonomous shopping assistants: Implemented to provide frictionless, personalized journeys for customers.
Digital sales growth: Achieved a 21% increase in digital sales, with penetration now at 9.5%.
E-commerce fulfillment: More than half of orders delivered in 3 hours or less, with 95% of delivery households eligible for Flash delivery in 30 minutes.
Pharmacy and health business: Sales increased by 18%, driven by immunizations, GLP-1 therapies, and core prescriptions.
AI in labor management: Deployed generative AI for labor forecasting and scheduling, reducing costs and improving associate experience.
Supply chain optimization: Implemented AI demand forecasting to enhance product tracking, forecasting accuracy, and on-shelf availability.
Productivity initiatives: Targeting $1.5 billion in productivity gains over the next 3 fiscal years through labor optimization, automation, and process simplification.
AI and technology transformation: Partnered with Google, OpenAI, and Databricks to scale AI solutions across the enterprise, enhancing decision-making and operational efficiency.
Loyalty program growth: Membership grew 12% to over 49 million members, with enhanced engagement and spending patterns.
Media collective expansion: On-site media delivered double-digit growth, leveraging loyalty data for targeted campaigns and monetization.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Government shutdown and SNAP delays: Temporary headwinds from the government shutdown and delayed SNAP funding negatively impacted identical sales by approximately 10 to 20 basis points, reflecting potential risks to revenue stability.
Consumer pressure across income segments: Low-income shoppers are stretched, putting fewer items in the basket and prioritizing essentials. Middle-income households are showing signs of softening with increased price sensitivity and trade-down behavior, while high-income customers are becoming more price-conscious. This could impact overall sales and profitability.
Inflation Reduction Act's Medicare Drug Price Negotiation Program: The program reduces consumer prices and supplier costs on certain branded drugs, resulting in lower reported pharmacy sales. This creates a 65 to 70 basis point headwind to identical sales in Q4, though profit impact is near neutral.
Competitive pressures in retail media: The retail media space remains highly competitive, which could challenge the company's ability to scale its media collective and maintain high-margin growth.
Labor negotiations: While agreements have been reached for most associates, 8,000 associates still have pending negotiations, posing potential risks to labor stability and operational continuity.
Digital and e-commerce profitability: The mix shift towards digital and pharmacy is impacting gross margins, reflecting challenges in maintaining profitability while scaling these segments.
Economic uncertainties: The mixed consumer environment and cautious discretionary spending across income segments could impact sales and strategic execution.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Identical sales growth for fiscal 2025 is expected to be in the range of 2.2% to 2.5%, reflecting the impact of the Inflation Reduction Act. Adjusted EBITDA is projected to be between $3.825 billion and $3.875 billion, including $65 million in adjusted EBITDA from the 53rd week.
Margin Projections: Gross margin is expected to be impacted by a mix shift towards digital and pharmacy, as well as targeted price investments. However, productivity benefits are expected to partially offset these investments.
Capital Expenditures: Capital expenditures for fiscal 2025 are projected to remain in the range of $1.8 billion to $1.9 billion, focusing on store upgrades, digital technology, and supply chain capabilities.
Pharmacy Business Outlook: The pharmacy business is expected to deliver profitable growth in 2025, supported by immunizations, value-added services, and efficiency initiatives. The Inflation Reduction Act will reduce reported pharmacy sales but is expected to have a near-neutral impact on profit.
Digital and E-commerce Growth: Digital sales are expected to continue growing, supported by AI-driven innovations and a store-based fulfillment model. The company aims to scale its e-commerce business profitably.
AI and Technology Transformation: The company plans to embed AI across the enterprise to drive productivity, optimize labor, enhance customer experience, and create structural cost advantages. These initiatives are expected to support long-term growth and profitability.
Loyalty and Customer Engagement: Loyalty membership is expected to grow, with enhancements to the program driving deeper engagement and higher spending. The loyalty platform will also support targeted marketing and monetization opportunities.
Retail Media Growth: The media collective is expected to scale, leveraging loyalty data and omnichannel reach to create a high-margin growth engine and unlock new monetization opportunities.
Productivity Gains: The company aims to achieve $1.5 billion in productivity gains over the next three fiscal years, focusing on labor optimization, automation, and process simplification.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Quarterly Dividend: Returned $77 million to shareholders through a quarterly dividend of $0.15 per share.
Accelerated Share Repurchase Program: Continued the $750 million accelerated share repurchase program, expected to be complete in early 2026.
Remaining Share Repurchase Authorization: $1.3 billion remains under the existing $2.75 billion authorization, which can be executed after the completion of the current ASR.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the overall pricing environment lined up relative to initial expectations, and is there much risk ahead for the need for incremental price investments?
A:The company is taking a surgical and targeted data-driven approach to price investments, seeing positive results in categories where investments have been made. Price gaps are market-driven and category-driven, with personalized loyalty discounts playing a significant role. The company intends to continue investing thoughtfully and sees price as one part of the value equation, alongside fresh capabilities, proximity, e-commerce, and pharmacy expertise.
Q:How is the company progressing with getting new pharmacy shoppers to purchase more grocery items, and are there any changes to timing or lifts given macro pressures?
A:The company is pleased with pharmacy growth, much of which is organic. Most pharmacy customers already shop for groceries, and deeper engagement occurs as they adopt digital platforms and loyalty programs. It takes 1-2 years for customers to fully engage with the loyalty platform. The company sees structural advantages in its services and is focused on deepening customer engagement.
Q:What are the key factors to consider for FY '26, including potential headwinds and confidence in achieving the algorithm?
A:The company is confident in its algorithm due to its 'Customers for Life' strategy, growth in pharmacy, digital, and customer engagement, media collective, value enhancement efforts, technology modernization, and productivity agenda. These initiatives build on one another, and the company has levers to pull to adapt to changing environments. The Inflation Reduction Act's impact on drug pricing is acknowledged, but the company remains confident in achieving its goals.
Q:What are the key drivers for the lower ID sales guide for this year, and how is the company addressing uncertainty in consumer behavior?
A:The lower ID sales guide is impacted by the Inflation Reduction Act's drug pricing issue, which accounts for a 65-70 basis point impact. The company is cautious about industry units and consumer behavior but is on track with expectations when excluding the Act's impact. Scenarios like GLP-1 adoption and macro pressures are being monitored.
Q:Can the company achieve its algorithm next year despite current unit volume and pricing pressures, and what are the levers to pull?
A:The company believes it can achieve its algorithm due to its agility and growth in digital platforms, pharmacy, customer experience, and price investments. The Inflation Reduction Act's impact is a top-line pressure but net neutral to the bottom line. The company is focused on leveraging its productivity and technology agenda to reinvest in value.
Q:What is the progress of cost savings and the cadence of savings for 2026?
A:The company is executing well against its $1.5 billion cost savings plan, driven by technology, automation, analytics, and process redesign. Productivity is fueling growth through reinvestment in price and customer experiences. New opportunities are expected in 2026, and the company is exceeding its productivity targets.
Q:What is the wallet share difference between upper decile loyalty members and average loyalty members, and how does pharmacy engagement impact this?
A:Digitally engaged customers spend 2-3x more than non-engaged customers, and engagement rises further with broader ecosystem participation. Pharmacy engagement increases spending to 4-5x. The company focuses on deepening customer engagement through personalized journeys and AI-driven tools.
Q:Have the divisions where price investments were made crossed into positive food volume territory, and is there potential to exit underperforming markets?
A:Price investment categories have shown strong unit improvement, with some moving to positive year-over-year. The company is evaluating its portfolio and may exit underperforming markets while focusing on growth in strong markets. Real estate operations are being sophisticated, and surplus assets are being evaluated.
Q:What is the outlook for gross margin in Q4, and how does it compare to Q3?
A:Q4 gross margin is expected to be more like Q2 due to a shift in pharmacy business from Q4 to Q3. Pharmacy margin is typically lower in Q4, and the company anticipates similar trends to Q2.
Q:What is the company's perspective on the GLP-1 pill format and its potential impact?
A:The company sees the GLP-1 pill format as a potential tailwind due to its accessibility and delivery mechanism. However, it is not expected to have a material impact on EBITDA in the short term, as it primarily affects the top line and benefits patients.
Q:What is the company's view on the promotional environment and its impact on pricing?
A:The company acknowledges a more aggressive promotional environment, especially during the holiday season. It leverages loyalty and AI-driven personalization to maintain a competitive edge. The company is a promotional merchant by nature and is leveraging its size and scale to secure better promotional funding.
Q:What is the composition of sequential unit trend improvement, and how does digital sales contribute to profitability?
A:Sequential unit trend improvement is attributed to surgical price investments and loyalty-led value. Customers are price-sensitive, with smaller baskets and trade-down behavior. Digital sales are growing, with over half of orders delivered in less than 3 hours. Profitability is improving with AI adoption, and the company expects to achieve profitability by the end of this year or next year.
Q:How is the shift to national buying progressing, and what are the implications for gross margin?
A:The shift to national buying is progressing well, with benefits expected in year 2 and 3 of the productivity program. AI-driven merchandising intelligence is optimizing profitability, and the company is bullish on capturing benefits in 2026 and beyond.
Q:What is the outlook for unit trends in core grocery categories and the performance of fresh versus branded products?
A:The company does not expect flat units in Q4 2025 due to negative industry trends. Price investment categories show strong unit inflection, and the company is confident in its pricing approach. Fresh and branded product performance aligns with expectations, supported by price investments and innovation.
Q:What are the trends across income demographics, and how does this differ in-store versus online?
A:Low-income customers show smaller baskets and focus on essentials, while middle-income customers exhibit trade-down behavior. High-income customers remain stable but are more value-conscious. The company leverages loyalty programs and personalized promotions to address these trends across in-store and online channels.
Q:What is the impact of pharmacy on ID sales and the inflation piece in Q3?
A:Pharmacy had a strong impact on ID sales in Q3, with inflation up 2%. The company passed through less than 2% and less than its cost inflation, as reflected in margins.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the inflation piece in Q3, only stating that CPI was up 2% and that they passed through less than their cost inflation. Additionally, they did not provide a clear breakdown of pricing versus units for ID sales excluding pharmacy. Responses to questions about the GLP-1 pill format's impact on EBITDA and the potential for exiting underperforming markets were also vague, lacking detailed data or concrete plans.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI enterprise
AI transformation
ASR
Inflation Reduction
Reduction Act
action
appeal
basket size
behavior
capacity
cost advantage
cost control
customer loyalty
decision
effort
essential
forecasting
foundation
fulfillment
government shutdown
immunization value
labor model
level customer
loyalty enhancement
monetization
pool
productivity gain
resilience model
shopping assistant
shutdown SNAP
speed
strength Life
team
trip
unit trend
value service
ACI Transcript
Albertsons Companies, Inc. (ACI) Q4 2025 Earnings Call Transcript
Positive4-14
The earnings call summary and Q&A session highlight several positive factors: consistent growth in digital and e-commerce, strong productivity initiatives, and strategic investments in AI and technology. Despite challenges like higher fuel costs and opioid settlements, the company plans to fund share repurchases through working capital improvements. The pharmacy business is expected to grow, and loyalty programs are enhancing customer engagement. While there are some concerns, such as unclear store expansion details, the overall sentiment is positive, indicating a likely stock price increase of 2% to 8%.
Cameco Corporation (CCO:CA) Presents at Goldman Sachs Energy, CleanTech & Utilities Conference Transcript
Neutral1-7
Albertsons Companies, Inc. (ACI) Q3 2026 Earnings Call Transcript
Positive1-7
The earnings call summary and Q&A session reveal strong growth in pharmacy and digital sales, optimistic guidance, and effective cost savings initiatives. Despite concerns about inflation and promotional environment, the company's strategic investments in technology and customer engagement are promising. Share repurchase plans and improved EPS guidance also contribute positively. Overall, these factors suggest a positive stock price movement over the next two weeks.
Albertsons Companies, Inc. (ACI) Q2 2025 Earnings Call Transcript
Unknown10-14
The earnings call presents a mixed outlook. While there are positive developments in digital platforms, pharmacy growth, and productivity initiatives, the unchanged EBITDA and EPS guidance, coupled with no significant margin changes, tempers enthusiasm. The Q&A reveals cautious optimism with a focus on strategic investments and AI integration, but lacks detailed timelines or strong financial impacts. Overall, the sentiment is balanced, leading to a neutral prediction.
ACI Slides
ACI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
